Overview

Extension Study of MT-1303

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation